Helicobacter pylori infection. Frequency of first-line treatment failure
Antibiotic resistance may hinder the efficacy of eradication therapy against Helicobacter pylori infection and it has become a major concern worldwide. Due to the relatively scarce evidence published in Argentina on this topic, our aim was to describe factors associated with H. pylori persistence after antibiotic treatment. The therapeutic failure rate was described among 81 patients with H. pylori gastritis treated in our Hospital with a post-treatment urea breath test to determine successful eradication. Mean age was 58 ± 12 and 43.2% were male subjects. H. pylori persistence was observed in 17.3% of subjects. Therapeutic failure was more common among patients receiving clarithromycin + amoxicillin therapy that among those receiving levofloxacin + amoxicillin (25% vs. 6.6%, p = 0.04). The following variables were assessed: age, gender, referral symptoms, smoking, anti-inflammatory use, diabetes, obesity, treatment type and duration. Clarithromycin-based therapy and male gender were associated with infection persistence on univariate analysis [OR 4.2 (1.1-15.6) and 5.2 (1.1-26.4)]. On multivariate analysis, clarithromycin-based was associated with infection persistence [5.38 (1.1-29.5)]. We conclude that clarithromycinbased therapy is significantly associated with treatment failure. This failure may be due to an elevated prevalence of H. pylori resistance to clarithromycin in the population under study and raises the question on the utility of such therapeutic alternative.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
Medicina - 80(2020), 2 vom: 01., Seite 111-116 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Infección por Helicobacter pylori. Frecuencia del fracaso del tratamiento de primera línea |
|---|
| Beteiligte Personen: |
Paz, Silvina [VerfasserIn] |
|---|
| Themen: |
6GNT3Y5LMF |
|---|
| Anmerkungen: |
Date Completed 05.06.2020 Date Revised 05.06.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM308673638 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308673638 | ||
| 003 | DE-627 | ||
| 005 | 20231225132231.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||spa c | ||
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308673638 | ||
| 035 | |a (NLM)32282315 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Paz, Silvina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Helicobacter pylori infection. Frequency of first-line treatment failure |
| 246 | 3 | 3 | |a Infección por Helicobacter pylori. Frecuencia del fracaso del tratamiento de primera línea |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.06.2020 | ||
| 500 | |a Date Revised 05.06.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Antibiotic resistance may hinder the efficacy of eradication therapy against Helicobacter pylori infection and it has become a major concern worldwide. Due to the relatively scarce evidence published in Argentina on this topic, our aim was to describe factors associated with H. pylori persistence after antibiotic treatment. The therapeutic failure rate was described among 81 patients with H. pylori gastritis treated in our Hospital with a post-treatment urea breath test to determine successful eradication. Mean age was 58 ± 12 and 43.2% were male subjects. H. pylori persistence was observed in 17.3% of subjects. Therapeutic failure was more common among patients receiving clarithromycin + amoxicillin therapy that among those receiving levofloxacin + amoxicillin (25% vs. 6.6%, p = 0.04). The following variables were assessed: age, gender, referral symptoms, smoking, anti-inflammatory use, diabetes, obesity, treatment type and duration. Clarithromycin-based therapy and male gender were associated with infection persistence on univariate analysis [OR 4.2 (1.1-15.6) and 5.2 (1.1-26.4)]. On multivariate analysis, clarithromycin-based was associated with infection persistence [5.38 (1.1-29.5)]. We conclude that clarithromycinbased therapy is significantly associated with treatment failure. This failure may be due to an elevated prevalence of H. pylori resistance to clarithromycin in the population under study and raises the question on the utility of such therapeutic alternative | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Helicobacter pylori | |
| 650 | 4 | |a clarithromycin | |
| 650 | 4 | |a gastritis | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Levofloxacin |2 NLM | |
| 650 | 7 | |a 6GNT3Y5LMF |2 NLM | |
| 650 | 7 | |a Amoxicillin |2 NLM | |
| 650 | 7 | |a 804826J2HU |2 NLM | |
| 650 | 7 | |a Clarithromycin |2 NLM | |
| 650 | 7 | |a H1250JIK0A |2 NLM | |
| 700 | 1 | |a Florez Bracho, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Lasa, Juan Sebastián |e verfasserin |4 aut | |
| 700 | 1 | |a Zubiaurre, Ignacio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina |d 1945 |g 80(2020), 2 vom: 01., Seite 111-116 |w (DE-627)NLM000007854 |x 1669-9106 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2020 |g number:2 |g day:01 |g pages:111-116 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2020 |e 2 |b 01 |h 111-116 | ||